(Q37139284)

18 August 2017

1 reference

title

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis (English)

1 reference

18 August 2017

1 reference

Marcia L Moss

1

1 reference

18 August 2017

Liora Sklair-Tavron

series ordinal

2

1 reference

18 August 2017

Raphael Nudelman

series ordinal

3

1 reference

18 August 2017

publication date

15 April 2008

1 reference

Nature Clinical Practice Rheumatology

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

300-309

1 reference

Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Role of cytokines in the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Adalimumab for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Etanercept for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Adalimumab for treating rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Infliximab for the treatment of early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

An essential role for ectodomain shedding in mammalian development

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment o

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Therapeutic benefits from targeting of ADAM family members

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Preclinical and clinical studies of MMP inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Targeting TACE-dependent EGFR ligand shedding in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Metalloproteases regulate T-cell proliferation and effector function via LAG-3

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Membrane-anchored CD40 Is Processed by the Tumor Necrosis Factor-α-converting Enzyme

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

TACE-induced cleavage of NgR and p75NTRin dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

SorLA signaling by regulated intramembrane proteolysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Regulated shedding of PAR1 N-terminal exodomain from endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0797

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0797

1 reference

18 August 2017

1 reference